- Shares of Navidea Biopharmaceuticals (NAVB +5.4%) are trading higher on the session.
- The company says it has submitted an sNDA for Lymphoseek in patients with head and neck cancer (Fast Track designation granted last week).
- The company calls the submission an "important step toward NAVB's goal of helping this patient population who generally face extensive surgery to properly stage their cancer."
- CEO Mark Pykett also notes that "if this sNDA is approved, Lymphoseek will be the only approved agent for SLN detection in this patient population." (PR)
Navidea Biopharma submits sNDA for Lymphoseek
Dec 17 2013, 15:22 ET